ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

“We developed a strong collaboration with Pionyr Immunotherapeutics on their initial antibody candidate, and we are enthusiastic about advancing a second antibody candidate into development. We consider Pionyr’s Myeloid Tuning approach to be ideally suited to target solid tumors and look forward to contributing to multiple programs with our CHO.RiGHT development and manufacturing platform. We have established a seamless team working across the two companies and are very pleased to expand our collaboration,” said Dr René Brecht, VP Process Science and Manufacturing.

Evan Greger, Pionyr VP of Process Development and CMC, added: “Pionyr is developing a novel class of antibody-based therapeutics that can alter the tumor microenvironment to favor immune-activating cells over immune-suppressing cells. After establishing a collaboration with ProBioGen in 2017 to advance our first Myeloid Tuning candidate into cell line development and clinical trials, we are enthusiastic to continue our partnership and advance a second antibody candidate. ProBioGen is an outstanding partner with well-respected development and manufacturing services. The CHO.RiGHT expression platform, combined with their experienced, committed team, is ideally suited for the rapid and successful advancement of our antibody programs into clinical trials.”